Epratuzumab Disease area studied Abbreviated title Phase Study ID Registry database Study results Publication (if available) Systemic Lupus Erythematosus Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Phase 2 SL0002 Terminated NCT00113971 Hobbs et al. Ann Rheum Dis. 2011;70(Suppl 3):319, abs THU0425. European League Against Rheumatism (EULAR) 2011. May 25-28, 2011;London, UK. Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 3 SL0003 Terminated NCT001113062005-000705-59 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322 Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Phase 3 SL0004 Terminated NCT003832142005-000706-31 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322 Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 3 SL0005 Terminated NCT00382837 Systemic Lupus Erythematosus Study of Epratuzumab in Systemic Lupus Erythematosus Phase 2 SL0006 Completed NCT00383513 Wallace et al. Rheumatology (Oxford);2013;52(7);1313-1322 Systemic Lupus Erythematosus Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Phase 2 SL0007 Completed NCT006243512007-002566-35 Wallace et al. Ann Rheum Dis;2014;73(1);183-190 Systemic Lupus Erythematosus Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Phase 2 SL0008 Completed NCT006608812007-002589-37 Wallace, D. J. et al. Arthritis Care Res (Hoboken);2016;68;4;534-543 Systemic Lupus Erythematosus Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (EMBODY 1) Phase 3 SL0009 Completed NCT012623652010-018563-41 LINKLINK Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 Systemic Lupus Erythematosus Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY 2) Phase 3 SL0010 Completed NCT012617932010-018565-26 LINKLINK Clowse et al. Arthritis Rheumatol; 2017; 69(2): 362-377 Systemic Lupus Erythematosus Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus (EMBODY4) Phase 3 SL0012 Completed NCT014085762010-020859-30 LINKLINK Systemic Lupus Erythematosus Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Phase 2 SL0027 Completed NCT01534403
